New plasma-reduced synthetic media, Fukushima cocktails, for the storage of platelets for transfusion

BACKGROUND: Donor plasma proteins are associated with non-hemolytic allergic reactions, such as urticaria or laryngeal edema, in platelet-transfusion recipients. Replacement of plasma with synthetic media from platelet concentrates (PCs) is considered to be effective in preventing such reactions. However, platelets preserved in media depleted of less than 10% plasma are reported to have functions inferior to those preserved in plasma. METHODS: Fukushima Cocktails (FCs) contain glycerol (25, 50 or 100mM), sodium acetate, glucose and other components. To test the effect and determine the most suitable concentration of glycerol for platelet preservation, functions of platelets including aggregation, hypotonic shock response and swirling pattern and released biochemicals were measured with platelets preserved in Fukushima Cocktails. The effects of residual plasma on platelet functions were also evaluated. Autologous platelets stored for 3 days in solution containing 50 mM glycerol were transfused into healthy volunteer donors to evaluate their safety and survival. RESULTS: The functions (aggregation and hypotonic shock response) of platelets preserved in Fukushima Cocktails with 10% residual plasma were preserved for 5-7 days as well as plasma controls, whereas platelets stored for 9 days in a medium lacking glycerol became swollen and beta-thromboglobulin and thromboxane B(2) increased. When the residual plasma was more than 5%, platelet functions including aggregation, hypotonic shock response and swirling pattern were well preserved for 7 days. The in vivo platelet survival rates at 24 and 48 h after transfusion of platelets stored for 3 days in Fukushima Cocktail were 77% and 60%, respectively, which were not less than autologous plasma-stored platelets. CONCLUSION: Glycerol at a concentration of around 50 mM has a beneficial effect on platelet preservation for more than 7 days. The results of these experiments indicate that platelets stored in Fukushima Cocktail should be useful clinically.     

Extended storage of platelets in a new plastic container. I. Biochemical and morphologic changes

A new polyvinyl chloride container plasticized with tri(2-ethylhexyl) trimellitate (PL 1240 plastic) was evaluated for use in extended platelet storage. Six leukocyte-rich platelet concentrates (mean, 0.6 X 10(9) white cells per bag; range, 0.3 to 1.0 X 10(9) per container) were prepared by removing as much of the platelet-rich plasma from blood as possible. The cells were stored at 22 degrees C on an end-over-end agitator. An average of 1.04 +/- 0.19 X 10(11) platelets was recovered, and the mean pH dropped from 7.23 on day 0 to 6.68 by day 5. At the completion of the storage period. PO2 averaged 80 torr, PCO2 was 35 torr, bicarbonate concentration was 0.5 mM, and lactate concentration 29.5 mM. Thirty-one additional units of platelet concentrates, not deliberately prepared to be leukocyte-rich, on day 5 had a pH of 6.75 +/- 0.39 (mean platelet yield, 0.97 +/- 0.21 X 10(11); PO2 and PCO2 averaged 50 and 48 torr, respectively). Following storage, the cells had an average phase microscopic morphology score of 244 (n = 17). Platelets appeared to be preserved well throughout storage when assessed by transmission and scanning electron microscopy. We conclude that platelets can be stored for 5 days in PL 1240 plastic containers with good preservation of pH and cell ultrastructure.     

Improved in-vitro quality of platelet concentrates stored in a dextrose-free synthetic medium

Summary. The licenced balanced salt solution Plasma-Lyte, buffered with a clinical solution of sodium bicarbonate, was evaluated as a suspending fluid for platelet concentrates. Platelets suspended in this medium showed better pH maintenance over 5 days of storage compared to platelets stored in plasma (7·0 vs 6·45, P < 0·001). This was reflected in improvements in in-vitro indicators of platelet viability hypotonic shock response (79 vs 48%, P < 0·05), aggregation to paired agonists (86 vs 62%, P < 0·05); and platelet size distribution (104 vs 119%, P < 0·001). Dissolved bicarbonate measurement showed less depletion of bicarbonate in the synthetic medium compared to plasma, which suggests a lower rate of lactate formation. A synthetic medium containing dextrose showed inferior platelet storage characteristics when compared to the plasmalyte/bicarbonate medium in a paired study (Day 5, pH 6·53 vs 6·9, P < 0·05). The results suggest that utilization of substrates other than dextrose allows platelets to metabolize without the accumulation of lactate that leads to pH drops during storage in plasma, and continue to support the feasibility of storing platelets in a non-plasma environment.     

Platelet glycolysis in platelet storage. IV. The effect of supplemental glucose and adenine

Platelet concentrates were prepared from blood collected in CPD, CPD- A1, and CPD-A3. CPD-A1 contains 1.25 times as much glucose as does CPD, and sufficient adenine to provide a final concentration of 0.25 mM; CPD- A3 contains twice as much glucose as does CPD, and sufficient adenine to provide a final concentration of 0.5 mM. The consumption of glucose and the production of lactate and pyruvate in the platelet concentrates during room temperature storage was not influenced by glucose or adenine concentration. There was no difference in the rates of fall of the pH of platelets collected in the three preservatives. However, the number of contaminating white blood cells had a significant effect on these parameters. It is suggested that minimizing the number of contaminating white blood cells in platelet preparations may prove to be an important factor in platelet preservation.     

GMA保存血小板的实验研究

目的:探讨葡萄糖甘露醇腺嘌呤(GMA)作为添加剂对血小板的保存效果。方法:将GMA替代血浆制备的浓缩血小板(GMA-PC)和以ACD血浆为介质的浓缩血小板(ACD-PC)置22℃水平摇箱内保存,于各时间段取样测定有关指标。结果:两组PC的血小板低渗休克反应和以ADP诱导的血小板聚集率随保存时间的延长平行降低,差异无显著性(P> 0.05),在保存120h 期间,GMA-PC的乳酸脱氢酶释放量低于ACD- PC,前者的形态积分则显著高于后者,提示用GMA 保存的血小板其形态和细胞膜的完整性优于用ACD血浆保存的血小板。结论:初步证实用GMA替代血浆制备和保存浓缩血小板具有可行性     

Platelet concentrates stored for 5 days in a reduced volume of plasma maintain hemostatic function and viability

BACKGROUND: Platelet concentrates prepared from whole blood are generally suspended in a standard volume of 50 to 60 mL of plasma and can be stored thus at 20 to 24 degrees C for up to 5 days. In vitro studies suggested that this plasma volume could be reduced to 30 to 35 mL without impairing platelet function. STUDY DESIGN AND METHODS: This study evaluated whether platelets stored for 5 days in a reduced volume (30-35 mL) of plasma maintained their in vivo viability, hemostatic function, and recovery in recipients. Paired autologous platelet survival studies were done in 20 adult volunteers to assess platelet viability. A rabbit ear bleeding-time model was used to compare the hemostatic effectiveness of human platelet concentrates stored for 5 days in the standard or reduced volume of plasma. Platelet recovery was compared in thrombocytopenic hospital patients. RESULTS: Paired platelet survival studies indicated no significant difference between the values in platelet concentrates stored for 5 days in the reduced volume of plasma and the values in those stored in the standard volume. In the animal model, there was no significant difference in the bleeding times achieved by either set of platelet concentrates. The platelet count increments in thrombocytopenic patients were measured. The platelet count increments in patients who received reduced-volume platelet concentrates were as good as the increments achieved in patients given standard-volume concentrates. CONCLUSION: The in vivo viability, recovery, and hemostatic function of platelets collected in polyvinylchloride plastic containers and stored in 30 to 35 mL of plasma for 5 days are maintained as well as those of platelets stored in 50 to 60 mL of plasma.     

Recovery and survival in vivo of platelet concentrates prepared with prostaglandin E1

In follow-up to previous studies showing that stimulators of adenylate cyclase inhibit the activation of platelets in platelet concentrates (PC), the posttransfusion recovery and survival of autologous platelets prepared and stored after the addition of prostaglandin E1 (PGE1) to platelet-rich plasma at a concentration of 1.3 X 10(-8) M were investigated. Six normal subjects were studied on the two occasions, using PC stored with and without PGE1 and radiolabeling with 51Cr. The mean recovery of platelets prepared with PGE1 (35.2 +/- 8.1%) was significantly lower (p less than 0.013) than that of routinely prepared platelet concentrates (46.3 +/- 9.4%). The mean life-spans of platelets prepared with and without PGE1 were 7.1 +/- 0.4 and 6.2 +/- 1.0 days, respectively (p = NS). Despite its ability to inhibit the activation of platelets during concentration and storage, prostaglandin E1 appears to reduce posttransfusion recovery of platelets significantly in this experimental model and cannot be recommended at this time as an adjunct for PC preparation.     

Response to Transfusion of Platelets Pooled from Multiple Donors and the Effects of Various Technics of Concentrating Platelets

In order to determine the effect of concentration and pooling of platelet rich plasma (PRP) from multiple donors on response to platelet transfusion, the results of investigations with various preparations of fresh platelets for transfusion were analyzed. Transfusions of multiple donor, pooled PRP and platelet concentrates (PC) were compared by study of response to 385 transfusions in 55 patients with thrombocytopenia. The mean platelet increment an hour after PRP transfusion was 55,000/5 units/sq. meter surface area of the recipient. The mean fraction of platelets surviving in the circulation on the second day was 36 per cent of the increment. The results of the multiple donor pools were similar to PRP transfused from single donors. On the other hand, concentration of platelets reduced the effectiveness of platelet transfusion by over 50 per cent. Several methods of preparation of platelet concentrates were compared. The effects of age of the concentrate, resuspending medium, anticoagulant, and centrifugation are enumerated. However, a controlled clinical transfusion study showed that the decreased response to PC transfusions was due mainly to the deleterious effects of high speed centrifugation (1,500 to 5,000 × g) employed in the process of concentrating platelets from PRP. No method of preparing platelet concentrates was shown to be superior. Although inferior to PRP in terms of response to transfusion, concentrates are valuable because of their ease of handling and clinical utility when large quantities of platelets in a small volume of fluid are indicated.     

Circulation and function of human platelets isolated from units of CPDA- 1, CPDA-2, and CPDA-3 anticoagulated blood and frozen with DMSO

Platelet concentrates (PC) were isolated by serial differential centrifugation from units of blood anticoagulated with one of the citrate-phosphate-dextrose-adenine solutions (CPDA-1, CPDA-2, CPDA-2). The platelet concentrates were frozen with six percent dimethylsulfoxide at 2–3 degrees C per minute and stored in a -80 degrees C mechanical freezer in polyvinyl chloride or polyolefin plastic containers. After frozen storage at -80 degrees C for up to three months, the concentrates were thawed at 42 degrees C within 2.5 to 4.0 minutes, washed with autologous plasma, two percent dimethylsulfoxide and 10 percent acid-citrate-dextrose solution, and then resuspended in plasma. The washed platelets were labeled with 51Cr and transfused back to the donor from whom they had been obtained. In vitro recovery from whole blood to platelet concentrate was 70.5 ± 17 percent (mean ± one SD). In vitro freeze-thaw-wash recovery determined by phase microscopy was 78.5 ± 12.8 percent, in vivo 51Cr platelet recovery two hours after transfusion was 41.3 ± 13.5 percent, and the platelets had a linear lifespan of about eight days. A single unit of previously frozen platelets shortened an aspirin- prolonged bleeding time two and 24 hours after infusion. Results were similar with platelets isolated from all three anticoagulants and stored in both plastics. The results also were comparable to previous findings in this laboratory with platelets isolated from ACD and CPD anticoagulated blood.     

Reversibility of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival

BACKGROUND: Determining reversible aspects of the platelet storage lesion may result in improved function and survival of transfused platelets. STUDY DESIGN AND METHODS: Using a model of high-dose (apheresis-derived) platelet concentrates (PC), functional changes imposed by transient adverse metabolic conditions (pH < 6.0 for 1-2 hr) that could be reversed by autologous plasma rescue followed by standard platelet storage were investigated. Whole-blood-derived PCs were transfused into a small number of normal volunteers to determine platelet recovery and survival. RESULTS: Without rescue, high-dose PCs developed severe in vitro functional derangements at the time of the pH nadir including 1) loss of resting morphology; 2) complete abrogation of osmotic recovery and platelet aggregation and glycoprotein IIb/IIIa up-regulation to agonist; and 3) decreased alpha-granule release. By contrast, spontaneous and agonist-induced binding of annexin V were unaffected by adverse metabolic conditions. Plasma rescue to an optimal pH improved morphology scores, stabilized osmotic recovery, and completely restored platelet secretory responses, as measured by aggregation, glycoprotein IIb/IIIa up-regulation, and alpha-granule release. In a limited number of studies, plasma rescue was accompanied by preserved in vivo platelet recovery and survival after autologous transfusion after 5 days of storage. CONCLUSION: Transient derangement of platelet metabolism, which does not increase membrane phosphatidylserine exposure, causes in vitro functional abnormalities that are fully reversed or stabilized by metabolic rescue. Preliminary data suggest that such rescued platelets may have normal posttransfusion recovery and survival.     

Roles of acetate and phosphate in the successful storage of platelet concentrates prepared with an acetate-containing additive solution

The development of a synthetic medium for platelet storage is an important goal in transfusion medicine. Its use would make large volumes of plasma available for fractionation and might improve the quality of platelets after storage. Several investigators have described successful storage in media containing acetate. The previous work of the authors showed that platelet concentrates (PCs) can be stored successfully for 5 days at 22 degrees C by using an additive solution (Seto sol) to replace 80 to 95 percent of the plasma usually employed as a suspending medium. Seto sol contains 23 mM (23 mmol/L) sodium acetate and 25 mM (25 mmol/L) sodium phosphate. The roles of acetate and phosphate in achieving successful platelet storage were studied in the work reported here. The concentration of acetate decreased linearly for 7 days at 0.61 +/− 0.11 mumol per day per 10(9) platelets in parallel with the disappearance of 1–14C or 2–14C acetate. There was no disappearance of tritiated acetate from PCs or of 1–14C acetate from platelet-free mixtures of plasma and Seto sol, which suggests that the disappearance of 14C acetate from PCs reflected oxidation to CO2, which could leave PCs through the walls of the plastic container. Since O2 consumption was 1.47 mumol per day per 10(9) platelets, and the oxidation of a molecule of acetate requires 2 molecules of oxygen, acetate oxidation accounted for approximately 85 percent of oxygen consumption by platelets. The pH of PCs stored in Seto sol was nearly constant for 7 days, whereas, without acetate, it fell to 6.4 +/− 0.1 on Day 5.(ABSTRACT TRUNCATED AT 250 WORDS)     

Survival of rabbit platelets labeled with gallium 67

The viability of rabbit platelets labeled with radioactive gallium was determined to analyze the feasibility of using platelets labeled with gallium 68 as an imaging reagent for positron emission tomography. Platelets were labeled with a complex of the longer lived gallium 67 and mercaptopyridine-N-oxide (MPO) or with sodium chromate Cr 51. Their survival after transfusion was measured. Labelling efficiency of 67Ga-MPO was 6.5% to 45.8% (26.8% +/- 2.8%) when platelets were suspended in saline solution, but was much lower (1.6% +/- 0.8%) in plasma. Platelets labeled with either radioisotope in a saline medium survived as well as platelets labeled with 51Cr in plasma. Recovery values 1 hour after transfusion and mean platelet survivals were 68.6% +/- 4.9% and 3.4 +/- 0.2 days for 67Ga in saline solution, 76.5% +/- 6.8% and 3.8 +/- 0.5 days for 51Cr in saline solution, and 73.7% +/- 7.4% and 3.6 +/- 0.5 days for 51Cr in plasma. Labeled platelet concentrates always contained extra radioactivity not firmly bound to viable platelets. A postlabeling wash in saline solution did not reduce this contamination and resulted in reduction of the number of viable platelets. The results showed that rabbit platelets labeled with 67Ga-MPO survived in the circulation as well as those labeled by a standard protocol with sodium chromate Cr 51.     

Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or -80 degrees C

BACKGROUND: Platelet concentrates (PCs) are currently stored at 22 degrees C under continuous agitation. Because of the potential risk of the overgrowth of bacteria in case of contamination, PC shelf life is limited to 5 days. A mixture of second-messenger effectors is being evaluated to determine if it has benefits for cold liquid storage and cryopreservation of platelets. STUDY DESIGN AND METHODS: PCs separated from whole-blood donations by the buffy coat method were randomly assigned (n = 6 each) to be stored for 5 days at 22 degrees C under continuous agitation or at 4 degrees C after treatment with a platelet storage medium (ThromboSol, LifeCell Corp. ). PCs were also cryopreserved with 6-percent DMSO (final concentration) or with ThromboSol plus 2-percent DMSO (final concentration) (TC). After storage, platelets were analyzed by flow cytometry, transmission electron microscopy, and aggregation and perfusion techniques. RESULTS: Cold liquid storage of ThromboSol-treated platelets resulted in a lower binding of coagulation factor Va on the platelet surface than on platelets stored at 22 degrees C. In transmission electron microscopy, a conversion to spherical morphology was seen in the case of cold liquid storage. No difference between ThromboSol-treated platelets stored at 4 degrees C and platelets stored at 22 degrees C was seen in perfusion studies. Cryopreservation in the presence of TC prevented the reduction in glycoprotein Ib and IV expression on platelet surface that is seen in 6-percent DMSO-cryopreserved platelets. Platelets cryopreserved in TC covered, by thrombus, a significantly greater percentage of the perfused surface after the freezing and thawing process. CONCLUSION: ThromboSol-treated PCs separated from whole-blood donations by the buffy coat method, stored at 4 degrees C for 5 days, or cryopreserved in the presence of TC, maintained in vitro functional activity comparable to that achieved by current methods of storage, although discoid morphology was not preserved during cold liquid storage with ThromboSol.     

Automated platelet-rich plasma collection: A survey of 5 years' experience

In 1984 we began collecting platelet-rich plasma (PRP) from volunteer donors to meet the increasing demand for platelet concentrates (PC) in our region. A panel of 700 donors now contributes 30% of PC issued. Each donation of 500–550 mL is secondarily processed to a PC of 150 mL containing a mean 1.7 × 10¹¹ platelets and 350–400 mL of platelet-poor plasma (PPP) for fractionation. The procedures are usually of 45 min duration. Platelet function is well preserved during 5 days of storage as measured by pH, lactate evolution, hypotonic shock response and ristocetin-induced aggregation, although there is a marked fall in aggregatory response to adenosine diphosphate (ADP) and collagen. The procedural complications relating to donors (5.7%), harnesses (0.3%) and machines (0.5%) (1988 figures) have remained at an acceptable level.     

Serotonin uptake at 22 degrees C of stored platelets

In order to ascertain the possibility that platelet serotonin uptake may occur during storage of platelet concentrates (PC) at 22 degrees C with agitation, the high-performance liquid chromatographic procedure was applied to determine serotonin uptake by platelets. Studies at 22 degrees C showed that platelets stored for 4 days exhibited a significant serotonin uptake with a Vmax value of 2.4 X 10(-19) mole/platelet/min and a Km value of 0.62 X 10(-6) M. Incubation of PC with 5 X 10(-6) M serotonin for 1 day at 22 degrees C increased their serotonin contents from 2.2 to 4.2 X 10(-7) mole/10(11) platelets. Thrombin stimulation caused about 80% release of intracellular serotonin from fresh as well as stored platelets, which contained standard serotonin in the same amount as the original amount. These results suggest that a significant serotonin uptake of platelets might occur during in vitro storage at 22 degrees C and stored platelets have retained abilities to sequester extracellular serotonin into dense granules.     

Plasma free fatty acid metabolism during storage of platelet concentrates for transfusion

New containers allow storage of platelet concentrates (PC) at 22 degrees C for up to 7 days, during which glycolytic and oxidative metabolism is vigorous. Recent evidence suggests that 85 percent of adenosine triphosphate regeneration is based on oxidative metabolism and that substrates other than glucose may be used. Because platelets can oxidize free fatty acids (FFA) as a possible source of energy during storage, the authors studied their availability, distribution, and turnover. Plasma FFA concentration was unchanged after 1 day of PC storage but significantly increased on Days 3, 5, and 7. Platelet-free plasma (PFP) stored under the same conditions as PC demonstrated a progressive increase in FFA, suggesting that some of the FFA accumulating in PC were derived from plasma rather than platelets. Indeed, during PC storage, plasma triglycerides decreased significantly, suggesting that they are a possible source of the increased levels of FFA found on Day 3 and thereafter. Thus, PC have a plasma FFA pool available continuously for oxidation during storage. Studies with radiolabeled palmitate suggested that FFA oxidation by platelets occurs during storage. The current findings show that plasma FFA could be a significant substrate for oxidative metabolism during storage of PC and that the oxidized FFA are replenished at least in part from plasma. These results may allow platelet storage to be improved, particularly in synthetic media.     

An in vivo comparison of CPD and CPDA-2 preserved platelet concentrates after an 8-hour preprocess hold of whole blood

To see if citrate-phosphate-dextrose-adenine-two (CPDA-2) anticoagulant- preservative had an effect on the viability of platelets, we studied autologous in vivo recovery and survival in humans for platelet concentrates prepared from six units of blood drawn into CPDA-2 and compared them to six units drawn into citrate-phosphate-dextrose (CPD). These units were prepared from whole blood held at room temperature for 8 hours after collection and were then stored for 3 days at 22 ± 2 degrees C. The recovery for platelets preserved in CPD was 39.0 +/0 4.8 percent and for platelets preserved in CPDA-2, 32.5 ± 4.4 percent. The difference was not significant (p greater than 0.10). In order to estimate population differences, in vitro effects on in vivo viability were also evaluated. Six in vitro variables were studied but only pH at 72 hours (r = 0.77), platelet count (r = 0.64), and morphology score (r = 0.66) correlated to recovery. Only pH at 72 hours significantly influenced recovery (p = 0.007). By adjusting for individual pH differences, mean recovery for platelets stored in CPD was 37.5 percent, and for platelets stored in CPDA-2, 34.0 percent. The mean lifespan was 6.7 ± 0.7 days for platelets preserved in CPD and 6.1 ± 1.0 days for those preserved in CPDA-2. Although hemostatic function was not studied, these data support in vitro observations that platelets preserved with CPDA-2 are not different from platelets preserved with CPD, even after 8-hours of storage of whole blood at room temperature prior to platelet concentrate preparation.     

Effectiveness of Platelet Transfusion in Leukemia and Aplastic Anemia

Hemorrhage resulting from thrombocytopenia in patients with acute leukemia and aplastic anemia can be controlled by platelet transfusions. Severe gross hemorrhage was rarely observed when platelet counts were higher than 20,000 per cu. mm. Transfusion of 1 × 10¹¹ platelets produced an average increment of 12–14,000 platelets per cu. mm./square meter (m²) of body surface in acute leukemia. One unit of platelet rich plasma (PRP) contains an average of 1 × 10¹¹ platelets and 4 PRP/m² twice weekly will maintain the platelets above 20,000 per cu. mm. most of the time. When very large doses of platelets are required in a small volume then platelet concentrates (PC), prepared by centrifuging PRP and removing most of the plasma, are used. PC are 80 to 90 per cent as effective as PRP in elevating the platelet count if prepared from plasma with a p H of 6.8 or less, achieved by the addition of citric acid.
The major hazard of platelet transfusion is posttransfusion hepatitis. This can be minimized by the use of plasmapheresis thus using the same donors repeatedly. In the presence of anemia platelets can be given effectively in fresh whole blood transfusions until the patient's hematocrit is raised.     

以海藻糖为添加剂冷藏保存血小板悬液的研究

本研究探讨以海藻糖(trehalose)为添加剂的血小板悬液冷藏保存方法。采用核素标记法检测血小板生存时间,用比浊法测定血小板聚集率,诱导剂为终浓度11.2μmol/L的ADP。采集兔心脏血,按常规方法制备浓缩血小板悬液(PCs),在悬液中加入50mg/ml的海藻糖,37℃水浴4小时后,放于4-8℃冰箱保存,冷藏12天后,测定血小板聚集功能和输入自身体内后的生存时间。结果表明:常温和冷藏储存24小时后的PC血小板聚集率分别为(75.3±9.8)%和(80.5±12.5)%;输入兔体内24、48和72小时时的血小板存活率分别为(78.1±7.9)%、(65.4±6.7)%、(57.5±7.2)%和(5.1±2.5)%、(2.8±2.0)%、(0.9±0.8)%。加入海藻糖的PC冷藏保存12天后,血小板聚集率为(77.8±9.5)%;输入体内24、48和72小时时的血小板存活率分别为(75.7±11.0)%、(67.0±8.5)%、(56.8±8.0)%,与常温保存24小时对照相比,两者相近,P值均>0.05。结论:海藻糖能保护冷藏储存的兔血小板,延长冷藏血小板在体内的生存时间,经海藻糖冷藏储存的兔血小板功能完好。     

Extension of platelet concentrate storage by addition of sodium bicarbonate

Viability of platelet concentrate (PC) stored in polyvinylchloride bags in an elliptical rotator at 22 degrees C (standard PC) was assessed by in vitro tests, and an alternate approach to extending the shelf-life of PC by the addition of hypertonic sodium bicarbonate (test PC) was investigated. The fall in the pH which occurred during storage in standard PC was arrested in test PC. Furthermore, platelets stored under these test conditions maintained their morphology better than in standard PC as judged by their mean platelet volume and platelet distribution width. Recovery of stored platelets from hypotonic shock at 37 degrees C following resuspension in fresh plasma was better for test platelets. Results indicated that platelets in standard PC were viable up to day 3 but were not viable at day 7. Platelets store better in PC to which sodium bicarbonate has been added and behave as viable platelets up to 7 days.